Pseudomyxoma peritonei medical therapy: Difference between revisions
Jump to navigation
Jump to search
Nima Nasiri (talk | contribs) |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{Nnasiri}} | {{CMG}}{{AE}}{{Nnasiri}} | ||
==Overview== | ==Overview== | ||
Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly | Pseudomyxoma peritonei (PMP) is a rare condition consisting of [[intraperitoneal]] [[mucinous]] [[tumors]] and [[ascites]], most commonly arising from [[mucinous]] [[tumors]] of the [[Vermiform appendix|appendix]] and less commonly from [[ovary]] and [[colon]]. Pseudomyxoma peritonei symptoms include [[abdominal distention]], [[bloating]], [[hernia]], [[infertility]]. It is a very uncommon [[tumor]] with an incident of 0.1 people per 100,000 per year [[prevalence]], slightly more common in [[female]] wiht median age of 50 years old at the time of diagnosis. [[Prognosis]] is very optimal and good in general. Pseudomyxoma peritonei is [[Histology|histologically]] classified into [[disseminated peritoneal adenomucinosis]] (DPAM), [[peritoneal mucinous carcinomatosis]](PMCA). Mainstay of treatment is cytoreduction surgery combined with [[hyperthermic intraperitoneal chemoperfusion]] (HIPEC). | ||
==Medical Therapy== | ==Medical Therapy== | ||
Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapy with [[mitomycin]] at 42°C.<ref name="ChenHuang2008">{{cite journal|last1=Chen|first1=Chin-Fan|last2=Huang|first2=Che-Jen|last3=Kang|first3=Wan-Yi|last4=Hsieh|first4=Jan-Sing|title=Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)|journal=World Journal of Surgical Oncology|volume=6|issue=1|year=2008|pages=118|issn=1477-7819|doi=10.1186/1477-7819-6-118}}</ref><ref name="Sugarbaker2006">{{cite journal|last1=Sugarbaker|first1=Paul H|title=New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?|journal=The Lancet Oncology|volume=7|issue=1|year=2006|pages=69–76|issn=14702045|doi=10.1016/S1470-2045(05)70539-8}}</ref><ref name="pmid19567401">{{cite journal |vauthors=Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M |title=Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience |journal=In Vivo |volume=23 |issue=4 |pages=639–44 |date=2009 |pmid=19567401 |doi= |url=}}</ref> | Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with [[intraperitoneal]] [[chemotherapy]] with [[mitomycin]] at 42°C.<ref name="ChenHuang2008">{{cite journal|last1=Chen|first1=Chin-Fan|last2=Huang|first2=Che-Jen|last3=Kang|first3=Wan-Yi|last4=Hsieh|first4=Jan-Sing|title=Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)|journal=World Journal of Surgical Oncology|volume=6|issue=1|year=2008|pages=118|issn=1477-7819|doi=10.1186/1477-7819-6-118}}</ref><ref name="Sugarbaker2006">{{cite journal|last1=Sugarbaker|first1=Paul H|title=New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?|journal=The Lancet Oncology|volume=7|issue=1|year=2006|pages=69–76|issn=14702045|doi=10.1016/S1470-2045(05)70539-8}}</ref><ref name="pmid19567401">{{cite journal |vauthors=Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M |title=Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience |journal=In Vivo |volume=23 |issue=4 |pages=639–44 |date=2009 |pmid=19567401 |doi= |url=}}</ref> | ||
== References == | == References == | ||
Revision as of 13:19, 3 April 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei medical therapy On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei medical therapy |
|
Risk calculators and risk factors for Pseudomyxoma peritonei medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]
Overview
Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly arising from mucinous tumors of the appendix and less commonly from ovary and colon. Pseudomyxoma peritonei symptoms include abdominal distention, bloating, hernia, infertility. It is a very uncommon tumor with an incident of 0.1 people per 100,000 per year prevalence, slightly more common in female wiht median age of 50 years old at the time of diagnosis. Prognosis is very optimal and good in general. Pseudomyxoma peritonei is histologically classified into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis(PMCA). Mainstay of treatment is cytoreduction surgery combined with hyperthermic intraperitoneal chemoperfusion (HIPEC).
Medical Therapy
Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapy with mitomycin at 42°C.[1][2][3]
References
- ↑ Chen, Chin-Fan; Huang, Che-Jen; Kang, Wan-Yi; Hsieh, Jan-Sing (2008). "Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)". World Journal of Surgical Oncology. 6 (1): 118. doi:10.1186/1477-7819-6-118. ISSN 1477-7819.
- ↑ Sugarbaker, Paul H (2006). "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?". The Lancet Oncology. 7 (1): 69–76. doi:10.1016/S1470-2045(05)70539-8. ISSN 1470-2045.
- ↑ Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M (2009). "Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience". In Vivo. 23 (4): 639–44. PMID 19567401.